Compare GDL & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDL | CSBR |
|---|---|---|
| Founded | 2006 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.7M | 82.7M |
| IPO Year | N/A | 2015 |
| Metric | GDL | CSBR |
|---|---|---|
| Price | $8.34 | $5.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 10.1K | 8.2K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 6.02% | N/A |
| EPS Growth | N/A | ★ 161.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,900,000.00 |
| Revenue This Year | N/A | $4.84 |
| Revenue Next Year | N/A | $11.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.81 | $5.50 |
| 52 Week High | $8.67 | $9.63 |
| Indicator | GDL | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 55.50 | 55.47 |
| Support Level | $8.39 | $6.11 |
| Resistance Level | $8.47 | $6.29 |
| Average True Range (ATR) | 0.10 | 0.25 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 67.12 | 84.68 |
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.